| BioLineRX BioLineRx’s ultimate mission is to improve the health of people throughout the world with compounds that make for better and longer lives. Founded in May 2003 by leaders in the Israeli life-sciences sector, BioLineRx is committed to bridging the gap between innovative R&D and the global pharmaceutical industry with proprietary therapeutic products demonstrating clinical proof of principle. BioLineRx is focused on the “sweet spot” of drug development - advancing projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. We partner with researchers to further the commercialization of promising compounds and enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. BioLineRx screens, investigates and then in-licenses promising drug candidates and technologies in a wide range of indications from leading academic institutions and biotech companies. The BioLineRx team designs and implements development plans from feasibility through Phase 2 clinical trials, and from day one actively seeks the optimal out-licensing partner to take new drugs through final approvals to the global market. |
 |
| Earlybird
Ventures Earlybird provides capital, know-how, management support and a large network of industry experts to selected European and North American new technology enterprises and innovative entrepreneurs. Its strategy is to be among the first venture investors in technology companies that seek to create new markets. Earlybird currently manages three funds totalling US $ / Euro 300 million in committed capital. Its investment focus lies on information technology, communications, healthcare and convergent technologies. With offices in Europe (Hamburg, Munich) and the US (Palo Alto), Earlybird is well positioned to take advantage of international opportunities and to assist its portfolio companies to gain access to the international market place and financial resources. Earlybird´s investment professionals have extensive finance and start-up operating experience and actively support portfolio companies. In addition, a network of experienced industry specialists serves on the advisory board and assists Earlybird and its portfolio companies in providing strategic advice and operational support. OFFICES: Managing Partners: Dr. Hendrik
Brandis, Roland Manger, Rolf Mathies, Dr. Christian G. Nagel |
 |
| Infineon Ventures Infineon Ventures is the venture capital subsidiary of Munich, Germany, based top-tier semiconductor company Infineon Technologies AG. Since its inception late 1998 Infineon Ventures has become a prime venture partner for early-stage companies in microelectronics and communications. Leveraging the vast resources of Infineon Technologies the company is uniquely positioned to deliver high financial returns on it‘s investments as well as to add significant strategic value, both to portfolio companies as well as to Infineon. Our investment strategy is oriented towards companies that create new markets, exploit pace-setting technologies or establish new applications in areas where microelectronics is or will be a key enabling technology. We invest into pre-IPO companies of all development stages with a special focus on seed and start-up phases. |
 |
| Katan Associates Your Global Capitalization
Partner Based in the world’s leading centers for biotechnology and biomedicare, Katan Associates brings together specialists from a diverse range of corporate and commercial backgrounds to advise firms on long term growth and capitalization solutions. Katan Associates focuses on five core areas of specialization in helping firms achieve their business growth.
Katan provides businesses and management teams with the tools and the infrastructure to grow and expand their business. To find out more, please visit our website at www.katanassociates.com Or contact Seth Yakatan, Partner, at 323.356.6321 or seth@katanassociates.com |
 |
| Kirchhoff Consult AG Kirchhoff Consult is a consulting company for capital market- and corporate communication. We are the leading agency in the creation of annual reports and the accompaniment of Initial Public Offerings. The three branches Equity Consult, Financial Communications and Corporate Communications are precisely tailored to the specific needs of our clients and are supported by an in-house Design-Agency. We have 37 employees and offices in Hamburg, Munich, Lucerne (CH) und Vienna (A). Contacts: |
 |
| Morgan Lewis
Morgan, Lewis & Bockius LLP (“Morgan Lewis”) is a leading international law firm with 19 offices worldwide: Frankfurt, London, Brussels, Paris, New York, Washington, Philadelphia, Los Angeles, San Francisco, Miami, Northern Virginia, Harrisburg, Pittsburgh, Princeton, Boston, Palo Alto, Irvine, Dallas and Tokyo. Founded 1873 in Philadelphia, the firm comprises 1,200 lawyers, practicing in all essential areas of commercial law. Opened in 1989, the Frankfurt office is a highly specialized office concentrating on projects and corporate transactions (in particular, Mergers & Acquisitions and takeover law), securities advice, technology-driven transactions and Life Sciences and IP projects, as well as German and European antitrust law. Lawyers are qualified in the German and other international jurisdictions (in particular in U.S. law) and are able and accustomed to handling complex cross-border assignments. The Frankfurt office is specialized in the following areas:
Our lawyers advise on the establishment, operation and financing of businesses in the UK covering mergers and acquisitions, joint ventures and debt and equity financings in the public and private markets, including listing on the London Stock Exchange as well as a specialist pharmaceutical and biotech team. |
 |
| SWX Swiss
Exchange The SWX Swiss Exchange ranks among the world’s most technologically advanced securities exchanges. Backed by the strength of Switzerland’s financial marketplace, it resolutely pursues an internationally oriented strategy. In transnational collaboration with partner organisations, the SWX Swiss Exchange provides first-rate securities exchange services to all parties involved. Not only is its broad product palette a convincing factor in this regard, but also its fully integrated and totally automated trading, clearing and settlement system that remains unique in the world. The SWX Swiss Exchange offers innovative, international companies access to the Swiss capital market. A public placement of securities in one of its trading segments affords companies a high degree of global visibility among investors. An initial public offering in Switzerland is an attractive opportunity for companies to raise equity capital, especially those in the life science, IT and micro- and nanotechnology industries. SWX Swiss Exchange |
 |
| Sponsors
of the Cocktail Reception: The American Stock Exchange® (Amex®) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRSSM. In its role as a national equities market, the Amex provides a range of personalized, value-added services tailored to meet the needs of small and mid-cap companies. The Amex is also the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Today, the Amex continues to lead the industry with over 120 listings. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. To learn more, call John McGonegal, Senior Vice President, Equities, at 212-306-1652, or visit www.amex.com |
 |